genotype 4

August 4, 2015August 4, 2015

FDA Approves Once-Daily TECHNIVIE for HCV Genotype 4

News

On July 2015, the US Food and Drug Administration granted final approval of AbbVie’s TECHNIVIE (ombitasvir, paritaprevir and ritonavir), a fixed-dose combination drug classified as a hepatitis C virus NS5A ... Read more

January 28, 2015January 28, 2015

Hepatitis C Treatment VIEKIRAX® + EXVIERA® Now EMA-Approved

News

The European Commission has granted marketing authorizations for AbbVie’s all-oral, interferon-free, short-course treatment with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets). This treatment was recently approved with or without ribavirin (RBV) for patients suffering ... Read more